ClinicalTrials.gg
Active, not recruitingNCT04431479Updated Jul 10, 2026

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

An observational study in Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center. Active, not recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Fred Hutchinson Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
211
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center — 3 open to participants now, 6 under way, none of them phase 3. Bronchiolitis Obliterans Syndrome · Fred Hutchinson Cancer Center.

Started
2020
the only one that year
Observational
3 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center, this one is the only one that started in 2020, is one of 3 observational ones, and was the 7th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

3 of the 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bronchiolitis Obliterans Syndrome by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This trial collects clinical data and blood samples to predict the quality of response to specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Collecting and analyzing clinical data and blood samples from patients with cGVHD before and after treatment initiation may help doctors identify changes that may predict treatment response.

Read the detailed description

OUTLINE: This is an observational study.

Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.

03

Conditions studied

  • Chronic Graft Versus Host Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic graft-versus-host disease (GVHD) who are starting a new therapy for GVHD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age 18 or older
  • Prior stem cell transplant, with any graft source, donor type, and prophylaxis
  • No evidence of persistent or progressive at the time of enrollment
  • Agrees to be evaluated at the transplant center before a new is started (may be concurrent with the enrollment visit), and later between 2-6 weeks, 3 months and 6 months after index treatment is started or if an additional new therapy is started before 6 months
  • Signed,

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with study procedures
  • Uncontrolled psychiatric disorder
  • Anticipated survival \< 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
211 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational (questionnaire, biospecimen, chart review)

    Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment, or at a treatment change visit if new therapy has not started.

    Procedure: Biospecimen Collection · Other: Medical Chart Review · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood sample

  • OtherMedical Chart Review

    Review of medical chart

    Also known as: Chart Review

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Complete questionnaire

06

What researchers measure

Primary outcomes

  1. Clinical Response according to the 2014 criteria

    At the assessments, the 9 provider-reported National Institute of Health (NIH) organ severity scores (skin, eye, mouth, esophagus, upper gastrointestinal \[GI\], lower GI, liver, lung, and joint manifestations) will be collected reflecting disease activity in the past week. All scored items are single 4-7 point Likert scales. Based on past work, we anticipate it will take approximately 8 minutes to conduct the physical exam and record the relevant results. Pulmonary function testing results will be collected if available. Response will be assessed according to the recommendations of the 2014 NIH response measures publication or any applicable updates.

    Time frame: Up to 6 months

  2. Time to next systemic treatment

    Any addition of another systemic cGVHD treatment for medical reasons will be considered a failure, whether added because of a new or worsening manifestation of cGVHD, used as a "steroid sparing agent," or substituted due to toxicity.

    Time frame: From the start of the index medication until the addition of another systemic chronic graft versus host disease (cGVHD) treatment with death and treated recurrent malignancy considered competing events, assessed up to 3 years

  3. Duration of treatment

    Duration of treatment is defined as the time until discontinuation of therapeutic systemic immunosuppression (adrenal replacement and topical/local therapies are allowed) without resumption for at least 3 months.

    Time frame: Up to 3 months

  4. Survival

    Time frame: From the start of the index medication to death with patients lost to follow up or alive at the conclusion of the study censored, assessed up to 3 years

  5. Non-relapse mortality

    Non-relapse mortality is defined as death in remission, and relapse is considered a competing risk.

    Time frame: Up to 3 years

  6. Patient-reported outcomes

    Will be assessed using Lee symptom scale and Patient Reported Outcomes Measurement Information System (PROMIS). The summary score of the Lee Symptom Scale and the PROMIS Global will be calculated according to the instructions of the developers. For analyses assessing change in quality of life, improvement or worsening of the Summary symptom score by 6 points or more or the PROMIS Physical or Mental Functioning scales by 5 points or more compared to baseline will be considered a clinically significant change.

    Time frame: Up to 3 years

07

Study locations

10 sites
08

References and documents

Publications

  • Hamilton BK, Onstad L, Carpenter PA, Pidala J, Chen G, Cutler C, El Jurdi N, Farhadfar N, Juckett M, Kitko CL, Lee CJ, Lee SJ. Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial. Am J Hematol. 2026 Jul 1. doi: 10.1002/ajh.70427. Online ahead of print. PubMed 42385358 ↗
  • Hamilton BK, Onstad L, Carpenter PA, Pidala J, El Jurdi N, Farhadfar N, Kitko CL, Lee CJ, Mehta R, Chen GL, Cutler C, Lee SJ. Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease. Contemp Clin Trials. 2024 Oct;145:107637. doi: 10.1016/j.cct.2024.107637. Epub 2024 Jul 20. PubMed 39038701 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Jul 2027, 84 months after the start.

Of 49 non-industry observational studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 75. This study's planned 84 months is above that.

Counting every sponsor, half of 57 studies reached it within 40 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2020
First posted
Jun 16, 2020
StartActual
Jun 29, 2020
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04431479
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jun 29, 2020
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

Stephanie J. Lee
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion